Jocasta Neuroscience has secured $35 million in a Series A funding round led by True Ventures, with participation from Moore Strategic Ventures, SC8 Investments, Glentura, the Yagan Family Foundation, and other investors. The funding will support the advancement of its lead compound, JN-0413, a proprietary formulation of the longevity protein a-Klotho, through Phase 1 single and multiple ascending dose clinical trials, and prepare for an Investigational New Drug (IND) application targeted for the fourth quarter of 2026.

The company’s approach is based on scientific discoveries by Dr. Dena Dubal at the University of California, San Francisco. Jocasta acquired exclusive rights to the a-Klotho technology, which was previously under development by Unity Biotechnology. Preclinical studies have shown significant cognitive enhancement in multiple species, including rodents and non-human primates, along with strong genetic evidence supporting its therapeutic potential in humans.

As part of the financing, Kevin Rose of True Ventures will join the board of directors, alongside co-founders Dr. Michael Davidson, serving as Chairman, and Dr. Albert Agro, Chief Executive Officer. Dr. Agro noted that the funding reflects strong investor confidence in a-Klotho’s potential to change the course of age-related cognitive decline.

The proceeds will also position Jocasta Neuroscience for potential strategic partnerships in the pharmaceutical sector as it advances JN-0413 toward clinical proof of concept.